April 25th 2025
After delays in the review of the COVID-19 vaccine—which missed its April 1 review deadline—the agency has requested new data.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
What Does the Addition of a Novavax COVID-19 Vaccine Mean?
June 14th 2021With the company reporting its data today and it applying for authorization with regulatory bodies internationally, and later this year with the US Food and Drug Administration (FDA), what does the prospect of this new vaccine mean to people in the US and internationally?
Watch
FDA VRBPAC Meeting Covers Myocarditis, Data in Pediatric Population, Immunobridging
June 10th 2021The committee members discussed their concerns about having sufficient data to make an informed decision around the risk vs. benefits for looking at potential FDA approvals for vaccines in this population group.
Read More
Gauging Public Trust in COVID-19 Vaccines
June 7th 2021Hesitancy is a hurdle we have been struggling with in general when it comes to vaccines, but even more so when it comes to COVID-19. Throw politicization and the nuances of EUA into this mix, and it’s not surprising we’re having to work exceedingly hard to expand vaccine uptake.
Read More